

Lenzilumab

| | |
|-----------|---|
| Cat. No.: | HY-P99207 |
| CAS No.: | 1229575-09-0 |
| Target: | SARS-CoV |
| Pathway: | Anti-infection |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

| | | |
|-------------|---|--|
| Description | Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies ^{[1][2]} . | |
| In Vivo | Lenzilumab (i.p., 10 mg/kg, daily, 10 days) inhibits GM-CSF without inhibiting the cellular function of CAR-T and enhances its antitumor activity in NSG mice ^[1] . | |
| | MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |
| | Animal Model: | NSG mice with CART19 cells ^[1] |
| | Dosage: | 10 mg/kg |
| | Administration: | Intraperitoneal injection; daily; 10 days |
| | Result: | Neutralized GM-CSF, had antitumor activity and improved the proliferation of cytokine release syndrome (CRS) and neuroinflammation (NI). |

REFERENCES

- [1]. Rosalie M Sterner, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019 Feb 14;133(7):697-709.
- [2]. Zelalem Temesgen, et al. GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study. Mayo Clin Proc. 2020 Nov;95(11):2382-2394.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA